Current treatments have had limited efficacy on these illness-related problems. New pharmacological strategies and products such as agents stimulating metabotropic glutamate 2/3 receptors125 and dopamine 1 receptor and 5HT1A agonists126 have recently been introduced in adjunct to antipsychotics, with some evidence of their ability to reduce negative symptoms and cognitive impairments, respectively. More research on new pharmacological strategies based on the current ones is needed to combat these two major deficits and concerns in schizophrenia.